Baiyang Pharmaceutical released its 2026 semi-annual report. In the first half of the year, it achieved operating revenue of 3.56 billion yuan, or 4.068 billion yuan after reverting to the two-invoice system, and net profit attributable to the parent of 225 million yuan, up 37.72% year-on-year. The company continued to focus on brand operations, with the D-Cal brand generating revenue of 1.05 billion yuan, up 16.01% year-on-year, ranking first in China's imported calcium supplement market for ten consecutive years. Ganxianle topped the list of proprietary Chinese medicines for liver diseases in China's public medical institution terminals with an 11.47% market share. The radiosurgery business centered on ZAP-X has been approved for marketing in 26 countries and regions worldwide, with more than 8,100 clinical applications, and plans to mass-produce 18 units in 2026. In terms of innovative drug deployment, the Class 1 innovative radiopharmaceutical Jiluntai has been approved for marketing, the strategically invested Jikun Pharmaceutical has completed Phase I clinical trials for its pulmonary fibrosis innovative drug JK1033, and the Cifu VAD artificial heart has surpassed 1,000 cumulative implantations worldwide. The company is transforming and upgrading from brand operations to a technology-innovation-driven pharmaceutical enterprise.
Qingdao Baheal Medical INC.Strategically invested Jikun Pharmaceutical completed Phase I clinical trials for its pulmonary fibrosis innovative drug JK1033
